Barry Lance
Endocrinology, Diabetes & Metabolism · Laurel, MDNPI 1316913577
Payments from drug & device makers
Across 125 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$790
- Novo Nordisk$376
- Corcept Therapeutics$149
- Mannkind Corporation$140
- Sanofi-aventis U.S. LLC$112
- Xeris Pharmaceuticals, Inc.$88
- plus $745 from 18 others
What the payments were for
- Food & beverage$2,36899%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 35 | $790 |
| Novo Nordisk | 24 | $376 |
| Corcept Therapeutics | 8 | $149 |
| Mannkind Corporation | 7 | $140 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Xeris Pharmaceuticals, Inc. | 5 | $88 |
| Shire North American Group Inc | 5 | $80 |
| AstraZeneca(2 entities) | 5 | $79 |
| Amarin Pharma, Inc. | 3 | $70 |
| Merck | 4 | $68 |
| Tandem Diabetes Care, Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $48 |
| Abbott | 2 | $47 |
| Boehringer Ingelheim | 3 | $47 |
| Novartis | 2 | $43 |
| Amgen(2 entities) | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| BETA Bionics, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,400 in reported general payments places this provider in the 55th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $44,485 |
| RybelsusSemaglutide | 18 | $40,715 |
| MounjaroTirzepatide | 17 | $33,939 |
| OzempicSemaglutide | 15 | $32,909 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,805 |
| Novolog FlexpenInsulin Aspart | 11 | $3,254 |
| Rosuvastatin Calcium | 111 | $3,243 |
| Colchicine | 14 | $2,398 |
| SynthroidLevothyroxine Sodium | 28 | $2,392 |
| Ezetimibe | 41 | $1,871 |
| Gabapentin | 35 | $1,363 |
| Bupropion XlBupropion Hcl | 22 | $1,351 |
| Metoprolol Succinate | 57 | $1,327 |
| Metformin Hcl ErMetformin Hcl | 55 | $1,197 |
| Potassium Chloride | 31 | $1,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $376 | $73,62533 claims |
| Boehringer IngelheimJardiance | $47 | $44,48528 claims |
| Lilly USA, LLCMounjaro | $790 | $33,93917 claims |
| AbbVieSynthroid | $17 | $2,39228 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $95649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Laurel
- Nicholas ArgentoLaurel$1.1M
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.